My question is why no demand for the stock with all the “potentials”??The valuation dropped and stayed at multi year lows due to uncertainty about all aspects of THTX’s operations. They have two commercial drugs which have potentials to show a healthy sale growth from a long time stagnant levels as they have lately made some changes such as more capable easier to manage in house sale force. We have seen some positive trends lately but the market wants to see a sustained longer terms of growth pattern. The issue is the question whether the R$D assets are value added or value lost. If one look
at their scientists/clinical staff they have a significant number of folks on their payroll!?all the unknowns about the R&D have been a reason for the low demand in my opinion. THTX’s R&D assets at the moment is perceived as high risk unknown reward operations even potentially a waste as one of the analysts commented about why even perusing the oncology project, well that’s a great question which should have been addressed…The investor presentation is down again and no replacement, no interaction with the broader market since that PR. It is their responsibility to protectively work on the (ALL)shareholder retention, improving brand image, attracting investment opportunities, improving stakeholder relations and mitigating against policies that may restrict access to the information needed making it possible to build an investment thesis. Just try to look at this company as a product in order to attract buyers the job is to market/sell it by providing as much ongoing information as possible from the launch and as long as the product is still in the market any adjustments/changes has to be communicated in timely manner otherwise the product looses credibility/competitiveness less demand harder sell later on!Point is these long and even in crucial times short periods of “unknowns/uncertainty” can cause lasting damage. The company said the oncology is paused the reports I read online say it’s halted! NASH went from hero to zero due to long periods of silence and too many twists and turns.
Its the company’s responsibility to explain with clarity why they see value and still perusing that opportunity the sooner the better. As many said we are in a dark lonely place and it is hard to convince others to join us thus low demand. Now is not the time to have the presentation down for weeks!
Yes they don’t and couldn’t know everything about this protocol amendment until it has been finalized the early thoughts and rationale behind it should have been discussed with the market. We can come with all excuses but clarity goes much further to build credibility than opacity in any business.